Eradication of Helicobacter pylori

Active Ingredient: Lansoprazole

Indication for Lansoprazole

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

For this indication, competent medicine agencies globally authorize below treatments:

30 mg twice daily for 7–14 days in combination with clarithromycin and amoxicillin or metronidazole

For:

Dosage regimens

Oral, 30 milligrams lansoprazole, 2 times daily -30 minutes before meals, over the duration of 7 to 14 days.

Detailed description

When selecting appropriate combination therapy consideration should be given to official local guidance regarding bacterial resistance, duration of treatment, (most commonly 7 days but sometimes up to 14 days), and appropriate use of antibacterial agents.

The recommended dose is 30 mg of Lansoprazole twice daily for 7 days in combination with one of the following:

  • clarithromycin 250−500 mg twice daily + amoxicillin 1 g twice daily
  • clarithromycin 250 mg twice daily + metronidazole 400−500 mg twice daily

H. pylori eradication rates of up to 90%, are obtained when clarithromycin is combined with lansoprazole and amoxicillin or metronidazole.

Six months after successful eradication treatment, the risk of re-infection is low and relapse is therefore unlikely.

Use of a regimen including lansoprazole 30 mg twice daily, amoxicillin 1 g twice daily and metronidazole 400−500 mg twice daily has also been examined. Lower eradication rates were seen using this combination than in regimens involving clarithromycin. It may be suitable for those who are unable to take clarithromycin as part of an eradication therapy, when local resistance rates to metronidazole are low.

Elderly

Due to reduced clearance of lansoprazole in older people an adjustment of dose may be necessary based on individual requirements. A daily dose of 30 mg should not be exceeded in older people unless there are compelling clinical indications.

Dosage considerations

Lansoprazole should be taken at least 30 minutes before food.

Active ingredient

Lansoprazole

Lansoprazole is a gastric proton pump inhibitor. It inhibits the final stage of gastric acid formation by inhibiting the activity of H+/K+ ATPase of the parietal cells in the stomach. The inhibition is dose-dependent and reversible, and the effect applies to both basal and stimulated secretion of gastric acid.

Read more about Lansoprazole

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.

⇈